What makes a peptide “pharmaceutical grade”?

What makes a peptide “pharmaceutical grade”?

Pharmaceutical-grade peptides have undergone the FDA approval process. This isn’t a rubber stamp. It’s years of clinical trials, extensive safety data, manufacturing facility inspections, and ongoing quality monitoring. Companies invest hundreds of millions of dollars to bring a single peptide through this process.

The FDA approval process for peptides involves multiple phases. First, preclinical studies establish basic safety and efficacy in laboratory and animal models. Then Phase 1 trials test safety in small groups of humans. Phase 2 trials evaluate efficacy and dosing. Phase 3 trials provide the large-scale data needed to demonstrate the drug works as claimed. Only after successfully completing all phases does the FDA consider approval.

Examples of FDA-approved peptide medications include semaglutide, marketed as Ozempic and Wegovy, for diabetes and weight loss. Liraglutide, sold as Victoza and Saxenda, treats similar conditions. Tirzepatide, branded as Mounjaro and Zepbound, represents the newest generation of GLP-1 receptor agonists. Insulin, perhaps the most famous peptide drug, has been saving lives for a century. Oxytocin is prescribed for labor induction. These are all peptides. They’re all legal to prescribe. They’re all pharmaceutical grade.

The FDA regulatory framework for peptide compounding

Understanding FDA regulations requires knowing about the 503A and 503B frameworks. These sections of the Federal Food, Drug, and Cosmetic Act govern how compounding pharmacies can prepare medications, including peptides.

Section 503A covers traditional compounding pharmacies that prepare medications in response to individual patient prescriptions. These pharmacies can compound drugs that aren’t commercially available, provided they follow specific rules. Section 503B covers outsourcing facilities that can compound drugs without individual prescriptions, but with more stringent FDA oversight.

For peptides, the FDA maintains a “bulks list” of substances that pharmacies can use in compounding. This list is divided into categories that determine what’s legal to compound.

Category 1 peptides: legal for compounding

Category 1 substances have been evaluated by the FDA and deemed acceptable for use in compounding. Pharmacies can legally compound these peptides when a physician writes a prescription for an individual patient with a documented medical need.

Currently, Category 1 includes a limited number of peptides. Sermorelin is one example, used for growth hormone optimization. Gonadorelin acetate has been added to this category. GHK-Cu was placed in Category 1, though notably not for injectable administration, limiting its use to topical applications for skin health and hair growth.

NAD+ can also be compounded under this framework, though it’s technically a nucleotide rather than a peptide. The Category 1 list represents the small subset of bulk substances the FDA considers safe enough for compounding use.

Category 2 peptides: banned from compounding

Category 2 is where most popular research peptides end up. These substances have been evaluated and the FDA has identified “significant safety risks” that preclude their use in compounding. Compounding pharmacies cannot legally prepare these peptides for human use, period.

The list includes many peptides you’ve probably heard about.

BPC-157 sits firmly in Category 2. The FDA cited immunogenicity concerns and impurity risks when making this determination. Despite the extensive anecdotal reports and animal studies suggesting benefits for injury healing, the FDA determined the safety data was insufficient for human compounding.

TB-500, also known as Thymosin Beta-4 fragment, is banned from compounding. So is AOD-9604, once touted as a fat loss peptide. Ipamorelin acetate, a growth hormone secretagogue, cannot be compounded. KPV, despite its promise for inflammation and gut health, is prohibited.

CJC-1295 with DAC is no longer available for compounding. Semax and Selank, popular for cognitive enhancement, are on the banned list. Melanotan II cannot be compounded. Epitalon, despite research suggesting longevity benefits, is prohibited.

This Category 2 designation means that even if your doctor wanted to prescribe these peptides, no legitimate compounding pharmacy can legally fill that prescription.

Category 3 peptides: insufficient data

Category 3 contains substances nominated for the bulks list but submitted without sufficient supporting information. These peptides haven’t been fully evaluated, so the FDA hasn’t made a determination about their safety for compounding. They exist in regulatory limbo, neither approved nor explicitly banned.

The practical effect is similar to Category 2, compounding pharmacies generally won’t compound Category 3 substances because the regulatory risk is too high without clear FDA guidance.